X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DR. DATSONS LABS - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DR. DATSONS LABS NOVARTIS/
DR. DATSONS LABS
 
P/E (TTM) x 295.1 -10.9 - View Chart
P/BV x 25.1 0.2 15,485.0% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 NOVARTIS   DR. DATSONS LABS
EQUITY SHARE DATA
    NOVARTIS
Mar-17
DR. DATSONS LABS
Mar-14
NOVARTIS/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs855126 680.7%   
Low Rs66631 2,154.0%   
Sales per share (Unadj.) Rs219.0133.0 164.7%  
Earnings per share (Unadj.) Rs19.10.2 12,597.2%  
Cash flow per share (Unadj.) Rs20.36.6 307.2%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs307.0128.8 238.3%  
Shares outstanding (eoy) m29.9631.66 94.6%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x3.50.6 590.0%   
Avg P/E ratio x39.8516.1 7.7%  
P/CF ratio (eoy) x37.511.8 316.3%  
Price / Book Value ratio x2.50.6 407.7%  
Dividend payout %52.40-   
Avg Mkt Cap Rs m22,7792,477 919.5%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,39356 2,487.5%   
Avg. sales/employee Rs Th9,736.2NM-  
Avg. wages/employee Rs Th2,066.8NM-  
Avg. net profit/employee Rs Th849.0NM-  
INCOME DATA
Net Sales Rs m6,5624,211 155.9%  
Other income Rs m70279 891.4%   
Total revenues Rs m7,2644,289 169.3%   
Gross profit Rs m259569 45.5%  
Depreciation Rs m36204 17.6%   
Interest Rs m7430 1.7%   
Profit before tax Rs m91713 7,222.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3456 5,657.4%   
Profit after tax Rs m5725 11,920.8%  
Gross profit margin %3.913.5 29.2%  
Effective tax rate %37.648.0 78.3%   
Net profit margin %8.70.1 7,648.8%  
BALANCE SHEET DATA
Current assets Rs m9,7316,852 142.0%   
Current liabilities Rs m1,8306,711 27.3%   
Net working cap to sales %120.43.3 3,595.4%  
Current ratio x5.31.0 520.7%  
Inventory Days Days49161 30.3%  
Debtors Days Days25318 7.9%  
Net fixed assets Rs m573,673 1.6%   
Share capital Rs m141317 44.4%   
"Free" reserves Rs m9,0563,761 240.8%   
Net worth Rs m9,1964,078 225.5%   
Long term debt Rs m01,671 0.0%   
Total assets Rs m11,49912,633 91.0%  
Interest coverage x128.41.0 12,472.1%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.3 171.2%   
Return on assets %5.03.4 146.3%  
Return on equity %6.20.1 5,285.5%  
Return on capital %10.17.7 131.0%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m129964 13.4%   
Fx outflow Rs m1,734607 285.6%   
Net fx Rs m-1,605357 -449.7%   
CASH FLOW
From Operations Rs m-3801,345 -28.2%  
From Investments Rs m4,208-2,256 -186.5%  
From Financial Activity Rs m-3,318-1,200 276.5%  
Net Cashflow Rs m510-2,111 -24.2%  

Share Holding

Indian Promoters % 0.0 4.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.0 -  
FIIs % 1.6 1.4 118.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 94.1 22.8%  
Shareholders   41,647 20,807 200.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  SANOFI INDIA  PANACEA BIOTECH  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - J.B.CHEMICALS COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS